Citius Oncology, Inc. Common Stock (CTOR) Stock Price

CTORStock
$0.77−57.10%52W
Market Cap$81.21M
P/E—
PEG Ratio—
Div yield—
Beta3.39

CTOR Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-11.47%
Price vs S&P 500 (4W)-25.19%
VGM Score58.98

CTOR Earnings Surprise History

QuarterReport dateEPS estimateEPS actualSurprise
Q2 2026-$0.07-$0.08-14.29%(-$0.01)
Q1 2026-$0.01-$0.27-2600.00%(-$0.26)
Q4 2025-$0.04-$0.06-50.00%(-$0.02)
Q3 2025-$0.06-$0.06+0.00%(+$0.00)
Q2 2025-$0.15-$0.08+46.67%(+$0.07)

CTOR Analyst Recommendations

Jun 2026
Jul 2026
Aug 2026
Sep 2026
4.14
4.14
4.14
4.14

Industry Peers — Pharmaceuticals(574)

SymbolValue ScoreGrowth ScoreMomentum ScoreP/S Ratio (TTM)Revenue Growth TTM (YoY)Gross Margin (TTM)EPS Growth (5Y)Price
CTORCitius Oncology, Inc. Common Stock
——C————$0.77
LLYEli Lilly & Co.DBA14.9x49.6%83.4%27.6%$1257.03
JNJJohnson & JohnsonDCB6.2x7.8%67.7%14.9%$255.56
ABBVABBVIE INC.DCA7.8x10.4%72.8%-2.9%$285.42
MRKMerck & Co., Inc.DCA5.4x4.6%77.3%21.2%$145.95
NVSNovartis AGCCB4.9x3.3%75.0%15.3%$150.62
AZNAstraZeneca PLCCBB4.3x8.6%81.3%21.9%$165.41
ABTAbbott LaboratoriesCCB3.9x8.1%56.8%8.2%$104.89
NVONovo-Nordisk A/SBCC3.5x5.6%80.7%20.7%$38.83
PFEPfizer Inc.CDA2.6x-0.2%74.7%-3.5%$29.58
VRTXVertex Pharmaceuticals IncDCB10.1x10.2%86.0%8.3%$499.74

About Citius Oncology, Inc. Common Stock

Citius Oncology is a biopharmaceutical company developing targeted cancer therapies through lower-risk approaches, including new formulations and expanded indications for approved drugs. The company leverages intellectual property and regulatory exclusivity to accelerate market entry while serving key cancer centers.